Alpha Compute Corp · NASDAQ:ALP
Alpha Compute — Portage Biotech — Investor Presentation (March 2024)
17 slides from Alpha Compute's investor presentation, Mar 7, 2024
Slide 1: Corporate Presentation
1 Corporate Presentation Nasdaq: PRTG March 2024
Slide 2: Legal Disclaimer
2 Legal Disclaimer Forward - Looking Information This presentation contains forward - looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 . Statements in this presentation that are not statements of historical fact are forward - looking stateme
Slide 3: Immuno-Oncology Company with Two Potential Best in Class Compounds in the Clinic
3 Immuno - Oncology Company with Two Potential Best in Class Compounds in the Clinic Investment Highlights Cost - Efficient Business Model Multiple Data Catalysts in 2024 and 2025 Experienced Leadership Team from Bristol Myers Squibb
Slide 4: Proven Leadership with Oncology and Financing Expertise
4 Proven Leadership with Oncology and Financing Expertise Board of Directors Gregory Bailey, MD Rob Glassman, MD Linda M. Kozick Jim Mellon Mark Simon Ian Walters, MD CEO, Chairman Rob Kramer, PhD CSO Allan Shaw CFO Justin Fairchild VP Clin Dev Brian Wiley CBO Steven Mintz St. Germain Capital Corp O
Slide 5: Our Formula for Success
5 Our Formula for Success De - Risked Development Structured to Create Significant Value Strong Academic & Industry Network First/Best in Class I/O Agents Potential for Large Returns • Compounds with broad targets, single agent activity • Address ~70 - 80% of patients that don’t respond • Randomized
Slide 6: Five Data Catalysts Anticipated to Drive Value
6 Five Data Catalysts Anticipated to Drive Value Adenosine Platform Final Data Interim Data # of PTS STAGE INDICATION ASSET SITC 2024 ASCO 2024 21 - 27 Phase 1a A2A exp Solid Tumors PORT - 6 (A2A) ASCO 2025 SITC 2024 18 Phase 1a* A2B exp Solid Tumors PORT - 7 (A2B) SITC 2025 ASCO 2025 20 Phase 1b* A
Slide 7: Adenosine Portfolio
Adenosine Portfolio Validated mechanism impacting multiple immune cells Opportunity to modulate adenosine in 4 different ways: PORT - 6 A2AR Antagonist PORT - 7 A2BR Antagonist PORT - 8 A2AR/A2BR Dual Antagonist PORT - 9 Gut - Restricted A2BR Antagonist
Slide 8: Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Targeting Adenosine in Cancer Immunotherapy to Enhance T - Cell Function; Virgano, et al; Frontiers in Immunology 2019 modified slightly and used under CC BY 4.0 8 TME=tumor microenvironment Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment Macrophage Treg T cell NK Cell
Slide 9: Difference in A2A Small Molecules
9 Difference in A2A Small Molecules 10+ hrs ^ single agent activity in mouse models Competitive inhibitors won’t block in settings of high adenosine ARCUS CORVUS Potency Selectivity 2.5 hrs ^ Portage’s PORT - 6 is potentially best in class for potency, selectivity and durability* Relative profiles o
Slide 10: Fast Follower with Precedent for Biomarker Selection
10 Fast Follower with Precedent for Biomarker Selection * Expression data from Labcorp % A2A high* Tumor type 50 RCC 38 BC 34 NSCLC 32 Gastric 26 Prostate Best % Change in Tumor Lesion by High/ Low A 2A R levels Enrich patient population with biomarker/clinical data iTEOS independent monotherapy act
Slide 11: SITC 2023 Monotherapy activity with favorable immunologic changes
11 SITC 2023 Monotherapy activity with favorable immunologic changes TT - 10=PORT - 6
Slide 12: PORT-7: Highly Selective and Potent A2B Adenosine Receptor Antagonist
12 PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages • Activity in 4T1, CT26, and other disease models (asthma, fibrosis, sickle cell) Data on File Binding Affinity Functional Receptor Antagonism
Slide 13: ADPORT-601: Adaptive Phase 1a/1b Study
13 ADPORT - 601: Adaptive Phase 1a/1b Study * Phase 1a Starting Dose (10 mg BID) (n=12 - 15) A2AR (PORT - 6) indications: A2BR (PORT - 7) indications: Colorectal Cancer, Non - small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer, Prostate Cancer with high A2B expression Prostate Cancer, Non -
Slide 14: Strong U.S. and Global IP Positions on Platforms and Products
14 iNKT Engager • Composition, formulations with antigens, other I/O agents • Liposomes/particles 2031 - 2041 Patent Exclusivity Strong U.S. and Global IP Positions on Platforms and Products Broad and deep intellectual property covering: Adenosine Antagonist • Composition of matter patents • Use pat
Slide 15: Key Upcoming Clinical Development Milestones
15 2024 2025 1H 2H 1H 2H Key Upcoming Clinical Development Milestones* ADPORT - 601 (PORT - 6) Phase 1b start *At conferences we will present multiple arms & tumor types, 2024 and beyond are planned depending on data and available liquidity ADPORT - 601 (PORT - 6) ASCO - Phase1b interim ADPORT - 601
Slide 16: Summary Financial Data
16 Summary Financial Data ~$7.4 million + Cash Balance (12/31/23) $ - Debt 19,778,225 * Shares Outstanding (12/31/23) 41.00% Insider Ownership 59.00% Public Float 2,342,160 Options & RSUs Outstanding (12/31/23) 9,631,580 # Warrants Outstanding (12/31/23) $(~3.4 million) Cash Burn During Quarter Ende
Slide 17: Novel, Clinical Stage I/O Portfolio with Small Molecule Focus
17 Novel, Clinical Stage I/O Portfolio with Small Molecule Focus • Manufacturing simplicity, low capital investment • Five potential phase 1b/2 clinical data reads over next 2 years* Engine for Efficient Drug Development & Commercialization • Expert scientific oversight • Lean structure with financi